PLoS Negl Trop Dis 15(9): e0009596. September 20, 2021 Authors: Reza A. Niles, Charles R. Thickstun, Horace Cox, Daniel Dilliott, Clara R. Burgert-Brucker, Emma
Déclaration du Comité d’Experts de Mectizan (CEM) sur l’utilisation du Mectizan® : Le Comité rappelle à nos pays partenaires que le Mectizan® est exclusivement
A Mectizan Expert Committee (MEC) Statement on the use of Mectizan® during the COVID-19 pandemic: The MEC reminds country partners that Mectizan is donated only
International Health, Volume 13, Issue Supplement_1, January 2021, Pages S55–S59 Published December 22, 2020 Authors: Alison Krentel, Margaret Gyapong, Deborah A McFarland, Olumide Ogundahunsi,
Malawi becomes the second country in sub-Saharan Africa to eliminate lymphatic filariasis (elephantiasis) LILONGWE, MALAWI, Oct. 28, 2020 — Today the World Health Organization
This is footage[1] of microfilariae was captured in a 59-year-old man’s anterior chamber of the eye. The man lives in an onchocerciasis-endemic area in
A recent study informed that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells and two preprint publications
Parasites Vectors 13, 258 (2020). Published May 15, 2020. Authors: Jérémy T Campillo, Cédric B Chesnais, Sébastien D Pion, Jacques Gardon, Joseph Kamgno, Michel
Yemen eliminates lymphatic filariasis (elephantiasis) SANA’A, YEMEN, 27 August 2019 : MSD (trade name of Merck & Co., Inc., Kenilworth, N.J., USA), GSK, and the
On June 14, 2018, the US FDA approved moxidectin as a treatment for onchocerciasis (river blindness). We applaud Medicines Development for Global Health (MDGH)
